Brand-name drug
Zepbound price, strengths & recalls
Brand of tirzepatide (generic)
Pharmacies pay $482.79 for 2.4 mL of Zepbound 12.5 mg/mL, 2.4 mL pen this week, and from $482.79 to $1,052.46 across its 12 priced strengths and forms. It has 28 recalls on record, none ongoing. Its official label last changed on September 2, 2026.
Brand- Fair cash price
- $565.71
- Strengths
- 12
- Makers
- 1
- Updated
- Nov 11
Zepbound price by strength
What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 5 mg/mL, 0.5 mL auto-injector Brand | $526.23 | $1,052.46 / 2 mL |
| 10 mg/mL, 0.5 mL auto-injector Brand | $526.10 | $1,052.19 / 2 mL |
| 15 mg/mL, 0.5 mL auto-injector Brand | $526.04 | $1,052.08 / 2 mL |
| 20 mg/mL, 0.5 mL auto-injector Brand | $526.07 | $1,052.14 / 2 mL |
| 25 mg/mL, 0.5 mL auto-injector Brand | $525.83 | $1,051.67 / 2 mL |
| 30 mg/mL, 0.5 mL auto-injector Brand | $525.93 | $1,051.86 / 2 mL |
| 4.17 mg/mL, 2.4 mL pen Brand | $201.39 | $483.33 / 2.4 mL |
| 8.33 mg/mL, 2.4 mL pen Brand | $201.20 | $482.88 / 2.4 mL |
| 12.5 mg/mL, 2.4 mL pen Brand | $201.16 | $482.79 / 2.4 mL |
| 16.7 mg/mL, 2.4 mL pen Brand | $281.78 | $676.28 / 2.4 mL |
| 20.8 mg/mL, 2.4 mL pen Brand | $282.23 | $677.36 / 2.4 mL |
| 25 mg/mL, 2.4 mL pen Brand | $281.68 | $676.02 / 2.4 mL |
Zepbound vs generic tirzepatide
There is no generic version of Zepbound on the market yet. Its last listed patent or exclusivity runs to July 22, 2039 - generics often follow, though court cases and settlements can move the date either way.
GenericTirzepatide pricesSupply status: shortages & recalls
Recalls
Showing the 6 most relevant of 28 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
What people paid for Zepbound
Bought it recently? Share the price, the pharmacy and how you paid - it's the most useful thing the next person can read.
Official label & what changed
These highlights do not include all the information needed to use ZEPBOUND safely and effectively. See full prescribing information for ZEPBOUND.ZEPBOUND® (tirzepatide) Injection, for subcutaneous useInitial U.S. Approval: 2022
WARNING: RISK OF THYROID C-CELL TUMORS
In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined
[see Warnings and Precautions (5.1) and Nonclinical Toxicology (13.1)].
ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
[see Contraindications (4)]. Counsel patients regarding the potential risk for MTC with the use of ZEPBOUND and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with ZEPBOUND
[see Contraindications (4) and Warnings and Precautions (5.1)].
WARNING: RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
In rats, tirzepatide causes thyroid C-cell tumors. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).
ZEPBOUND is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (4, 5.1).
Recent major changes (as listed on the label)
Dosage and Administration (2.4)
| 01/2026
|
Warnings and Precautions
| |
Severe Gastrointestinal Adverse Reactions (5.2)
| 02/2026
|
Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus (5.8)
| 08/2026
|
Suicidal Behavior and Ideation (Removed) | 02/2026
|
Never Share a ZEPBOUND KwikPen Between Patients (5.10)
| 01/2026
|
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Approval, patents & generics
- Application
- NDA217806 · Eli Lilly And Co
- First approved
- November 8, 2023 (3 years ago)
- Latest approved change
- August 26, 2026
- Approved label
- PDF, Sep 10, 2026
- Generic makers
- None on the market
- Last patent listed
- July 22, 2039
- Exclusivity ends
- December 20, 2027
Patent dates are what the maker lists with FDA. Generic launch dates are often set by court rulings or settlements instead. Upcoming generics.
Zepbound questions
How much does zepbound cost without insurance?
Pharmacies pay about $482.79 for 2.4 mL of zepbound 12.5 mg/mL, 2.4 mL pen ($201.16 per mL). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $565.71. If you're quoted much more, check your quote and ask for the pharmacy's cash price.
Is there a generic for Zepbound?
Yes: tirzepatide. Compare tirzepatide prices.
Is zepbound in shortage?
No shortage is reported for zepbound right now. We check the national shortage list every day.
Has zepbound been recalled?
28 recalls on record, none ongoing. Recalls name specific lots - check yours.
When did the zepbound label last change?
The official label was last updated on September 2, 2026 (version 40). See what changed.
Talk about zepbound
No comments yet. Questions, tips, what worked for you - start the conversation.